High-sensitivity C-reactive Protein (hs-CRP)

CRP belongs to the pentraxin superfamily of pattern-recognition proteins. It binds phosphocholine on damaged cells and foreign pathogens, activating the complement cascade and opsonising targets for phagocytosis. While acutely elevated CRP is protective, chronically elevated low-grade CRP reflects persistent inflammatory signalling from adipose tissue, vascular walls, or smouldering infection.

Standard CRP assays detect concentrations ≥5-10 mg/L (relevant for acute infection and major inflammation). High-sensitivity CRP (hs-CRP) assays are validated to detect values as low as 0.1-0.3 mg/L and are necessary for cardiovascular risk assessment, where the relevant range is 0.5-10 mg/L.

hs-CRP is a downstream reporter of upstream cytokine activity — primarily IL-6. It is a sensitive but non-specific marker; any inflammatory stimulus (illness, injury, autoimmune flare, visceral obesity) elevates it. Results should therefore always be interpreted in clinical context and ideally confirmed with a repeat in the absence of acute illness.

Cardiovascular risk stratification (ACC/AHA/Reynolds criteria): Low risk: hs-CRP <1.0 mg/L; Moderate risk: 1.0-3.0 mg/L; High risk: >3.0 mg/L. Values >10 mg/L likely reflect acute infection or injury and should not be used for cardiovascular risk assessment without investigation.

The JUPITER trial (rosuvastatin vs. placebo in subjects with LDL <3.4 mmol/L but hs-CRP ≥2.0 mg/L) demonstrated that statin therapy reduced cardiovascular events in the setting of elevated hs-CRP even with 'normal' LDL — establishing hs-CRP as an independent risk marker actionable for treatment decisions.

hs-CRP adds independent predictive value beyond the Framingham risk score, particularly in intermediate-risk individuals. It is incorporated into the Reynolds Risk Score for women, and is increasingly used to refine CVD risk stratification in men in primary prevention settings.

Visceral adipose tissue is a major source of IL-6 and TNF-α — the primary drivers of hepatic CRP production. Consequently, hs-CRP correlates strongly with waist circumference, HOMA-IR, and metabolic syndrome components. Men with central obesity and chronically elevated hs-CRP (>2-3 mg/L) are at significantly higher cardiometabolic risk than their BMI alone would predict.

Inflammation suppresses the HPG axis: IL-1β, IL-6, and TNF-α all inhibit GnRH, LH, and direct Leydig cell testosterone production. Chronically elevated hs-CRP is therefore associated with lower testosterone in cross-sectional studies, though the causality is bidirectional — testosterone itself has anti-inflammatory properties.

Sleep-disordered breathing (obstructive sleep apnoea) is a potent driver of elevated hs-CRP via intermittent hypoxia-induced inflammatory signalling. OSA is also a major cause of testosterone suppression and metabolic dysfunction, making hs-CRP a useful integrative marker in men presenting with fatigue, low testosterone, and obesity.

hs-CRP is most actionable when persistently elevated (>2-3 mg/L on two separate draws, excluding acute illness) in men with borderline metabolic risk. In this context it should prompt assessment of metabolic syndrome, OSA screening, dietary review, and optimisation of lipid-lowering therapy.

Lifestyle interventions reduce hs-CRP substantially: regular aerobic exercise reduces hs-CRP by 20-35%; a Mediterranean-style diet reduces it by 15-25%; weight loss (even 5-10% body weight) produces significant reductions.

Statin therapy reduces hs-CRP by approximately 35-50% independent of LDL reduction (pleiotropic anti-inflammatory effect). This provides part of the mechanistic basis for the JUPITER trial findings.